Saturday, July 10, 2021 11:02:50 PM
My post was not about whether he did the right thing from the company standpoint in the long-term sense.
You can call it incompetent. In retrospect, given how things turned out after the short attack and trials and now, of course one wishes they just did the offering and cared not for the new investors who bought above $5. But generally new "investors" hate it when a company hits them with an offering. Keep in mind that stock price did not go up based on solid results, but on covid hope and hype.
But I see it as a deliberate decision; if he wanted to raise, they could have done so. They did not. What was the thinking?
One possibility is it had something to do with that philosophy of not screwing shareholders by raising money in such and such manner. (What that "manner" was will be a matter of speculation or partial information; I don't know what all the variables were.) The decision not to do hard offering at that time would be consistent with such an idealism there. It may not be the only factor but it is reasonable that it was one of them.
Now, you all producing this or that other example - as if you know all the ins and outs of such decisions - need not negate absolutely the possibility that Nader indeed is nobler than you make him out to be, that a lot of what he said in that proactive video of his philosophy and money-raising approach is indeed true. You can make your case and imagine you proved things about how anti-shareholder and self-interested he was. I don't buy the simple picture.
You can call it incompetent. In retrospect, given how things turned out after the short attack and trials and now, of course one wishes they just did the offering and cared not for the new investors who bought above $5. But generally new "investors" hate it when a company hits them with an offering. Keep in mind that stock price did not go up based on solid results, but on covid hope and hype.
But I see it as a deliberate decision; if he wanted to raise, they could have done so. They did not. What was the thinking?
One possibility is it had something to do with that philosophy of not screwing shareholders by raising money in such and such manner. (What that "manner" was will be a matter of speculation or partial information; I don't know what all the variables were.) The decision not to do hard offering at that time would be consistent with such an idealism there. It may not be the only factor but it is reasonable that it was one of them.
Now, you all producing this or that other example - as if you know all the ins and outs of such decisions - need not negate absolutely the possibility that Nader indeed is nobler than you make him out to be, that a lot of what he said in that proactive video of his philosophy and money-raising approach is indeed true. You can make your case and imagine you proved things about how anti-shareholder and self-interested he was. I don't buy the simple picture.
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
